Trailer Eliquis 'effective and reduced bleeding risk' in VTE trial
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb (BMS) and Pfizer's blood clot treatment Eliquis (apixaban) is as effective as warfarin in treating venous thromboembolism (VTE), and caused far less bleeding, according to Phase III data from the AMPLIFY trial.